Copyright
©The Author(s) 2022.
World J Clin Cases. Mar 6, 2022; 10(7): 2115-2126
Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2115
Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2115
Variables | Before PSM | After PSM | ||||
BOTs (n = 192) | EOC (n = 371) | P value | BOTs (n = 192) | EOC (n = 192) | P value | |
Age at diagnosis (years) | 41.0 ± 15.2 | 51.0 ± 11.8 | < 0.0001 | 41.0 ± 15.2 | 45.8 ± 12.8 | 0.0008 |
Body mass index (kg/m2) | 22.6 ± 3.2 | 23 ± 8.1 | 0.5159 | 22.6 ± 3.2 | 22.4 ± 3 | 0.5189 |
Menopausal status (%) | < 0.0001 | 0.565 | ||||
Premenopausal | 143 (74.5) | 176 (47.4) | 143 (74.5) | 138 (71.9) | ||
Postmenopausal | 49 (25.5) | 194 (52.3) | 49 (25.5) | 54 (28.1) | ||
Unknown | 0 (0) | 1 (0.3) | 0 (0) | 0 (0) | ||
Parity (%) | < 0.0001 | < 0.0001 | ||||
Nulliparous | 6 (3.1) | 0 (0) | 6 (3.1) | 0 (0) | ||
Parous | 133 (69.3) | 334 (90) | 133 (69.3) | 164 (85.4) | ||
Unknown | 53 (27.6) | 37 (10) | 53 (27.6) | 0 (0) | ||
Preoperative CA125>35 IU/mL (%) | < 0.0001 | < 0.0001 | ||||
Elevated | 107 (55.7) | 320 (86.3) | 107 (55.7) | 163 (84.9) | ||
Normal | 76 (39.6) | 37 (10) | 76 (39.6) | 19 (9.9) | ||
Unknown | 9 (4.7) | 14 (3.8) | 9 (4.7) | 10 (5.2) | ||
Preoperative CA199>34 IU/mL (%) | 0.945 | 0.827 | ||||
Elevated | 54 (28.1) | 104 (28) | 54 (28.1) | 58 (30.2) | ||
Normal | 110 (57.3) | 209 (56.3) | 110 (57.3) | 104 (54.2) | ||
Unknown | 28 (14.6) | 58 (15.6) | 28 (14.6) | 30 (15.6) | ||
Tumor localizations | 0.153 | 0.196 | ||||
LO | 44 (22.9) | 99 (26.7) | 44 (22.9) | 54 (28.1) | ||
RO | 86 (44.8) | 165 (36.4) | 86 (44.8) | 69 (35.9) | ||
Unknown | 62 (32.3) | 137 (36.9) | 62 (32.3) | 69 (35.9) | ||
FIGO stage (%) | < 0.0001 | < 0.0001 | ||||
Ⅰ | 168 (87.5) | 151 (40.7) | 168 (87.5) | 85 (44.3) | ||
Ⅱ | 7 (3.6) | 34 (9.2) | 7 (3.6) | 16 (8.3) | ||
Ⅲ | 17 (8.9) | 169 (45.6) | 17 (8.9) | 80 (41.7) | ||
Ⅳ | 0 (0) | 17 (4.6) | 0 (0) | 11 (5.7) | ||
Surgical type (%) | 0.0005 | 0.0005 | ||||
BSO | 7 (3.6) | 4 (1.1) | 7 (3.6) | 1 (0.5) | ||
HB | 13 (6.8) | 8 (2.2) | 13 (6.8) | 4 (2.1) | ||
HBO | 5 (2.6) | 31 (8.4) | 5 (2.6) | 17 (8.9) | ||
HBOA | 8 (4.2) | 15 (4) | 8 (4.2) | 11 (5.7) | ||
HBOL | 77 (40.1) | 291 (78.4) | 77 (40.1) | 146 (76) | ||
TR | 34 (17.7) | 6 (1.6) | 34 (17.7) | 5 (2.6) | ||
USO | 48 (25) | 13 (3.5) | 48 (25) | 7 (3.6) | ||
CS | 0 (0) | 3 (0.8) | 0 (0) | 1 (0.5) | ||
Postoperative adjuvant therapy (%) | < 0.0001 | < 0.0001 | ||||
Yes | 64 (33.3) | 292 (78.7) | 64 (33.3) | 156 (81.3) | ||
No | 125 (65.1) | 78 (21) | 125 (65.1) | 36 (18.8) | ||
Unknown | 3 (1.6) | 1 (0.3) | 3 (1.6) | 0 (0) |
- Citation: Gong XQ, Zhang Y. Develop a nomogram to predict overall survival of patients with borderline ovarian tumors. World J Clin Cases 2022; 10(7): 2115-2126
- URL: https://www.wjgnet.com/2307-8960/full/v10/i7/2115.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i7.2115